ai3Bio
ai3Bio develops therapies designed to remove disease-causing Th17 immune cells, using antibody and lipid-nanoparticle platforms to address autoimmune disease.
$48MSeries A
LeadZC
Ziff Capital Partners
Activity from announced rounds
Activity in this selectionUnited States · Oct 9, 2026 · Jan 1, 2026
Ziff Capital Partners is the firm named in Stellular and ai3Bio coverage, with ai3Bio identifying it as founding investor and co-lead.
Recorded funding activity
Stellular develops biologics for ocular disease. Ai3Bio develops therapies targeting Th17 immune cells. The pending relationship stays in draft while the firm’s event-specific roles are preserved.
- Rounds participated in
- 2
- Confirmed lead rounds
- 1 1 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $48M 1 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionStellular Bio
Develops platelet-derived regenerative biologic therapeutics for ocular surface diseases
UndisclosedSeries A
Role not disclosed